Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Genetics, LABS Partner on Genetic Testing

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – LABS and Ambry Genetics today announced a deal for the provision of testing services in reproductive health.

The deal, which the two firms said will result in services being available to a wider client base, will make Ambry the preferred provider of genetic carrier screening for LABS. Under the terms of the deal, LABS' customers will be able to access AmbryScreen, a genetic screen for identifying carriers of severe and common childhood diseases affecting pan-ethnic populations, the companies said in a joint statement.

"This partnership brings two premier laboratories together to offer new donor and patient screening options combined with an elite level of service that is unparalleled in the reproductive health industry," Elizabeth Hearty, CEO of LABS, said in the statement. "Ambry also brings to the table strong innovation and cutting-edge technologies within the genetic diagnostic market and that will effectively serve our clients."

Financial and other terms of the deal were not disclosed.

Ambry, based in Aliso Viejo, Calif., is a CLIA-certified specialty laboratory focused on genetic testing and diagnostic services. LABS is a transplant medicine reference laboratory headquartered in Centennial, Colo.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.